Advanced search
Publication Cover
Cancer Biology & Therapy Volume 18, 2017 - Issue 12
Submit an article Journal homepage
2,011
Views
8
CrossRef citations to date
0
Altmetric
Research Papers

Deactivation of cisplatin-resistant human lung/ovary cancer cells with pyropheophorbide-α methyl ester-photodynamic therapy

Guanhua QianKey Medical Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
,
Li WangKey Medical Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
,
Xueling ZhengKey Medical Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
&
Tinghe YuKey Medical Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaCorrespondence[email protected]
Pages 984-989 | Received 25 Aug 2017, Accepted 24 Sep 2017, Published online: 17 Nov 2017

References

  • Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. European journal of pharmacology. 2014;740:364–378.
  • Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H. Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer chemotherapy and pharmacology. 2015;75(6):1217–1227.
  • Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell death & disease. 2014;5:e1257.
  • Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT. Journal of photochemistry and photobiology B. 2009;96(1):1–8.
  • Oniszczuk A, Wojtunik-Kulesza KA, Oniszczuk T, Kasprzak K. The potential of photodynamic therapy (PDT)—Experimental investigations and clinical use. Biomedicine & Pharmacotherapy. 2016;83:912–929.
  • Park YK, Park CH. Clinical efficacy of photodynamic therapy. Obstet Gynecol Sci. 2016;59(6):479–488.
  • Szymanski W, Reeßing F. Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy. Curr Med Chem. 2016;23:1–46. doi:10.2174/0929867323666160906103223.
  • Hu W, Jin P, Liu W. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin. Cell Physiol Biochem. 2016;38(3):1199–1208.
  • Han X, Zhen S, Ye Z, Lu J, Wang L, Li P, Li J, Zheng X, Li H, Chen W, et al. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. Cell Physiol Biochem. 2017;41(3):973–986.
  • Zhang Y, Li J, Yu T. Pharmacokinetic profiles of cancer sonochemotherapy. Expert Opin Drug Deliv. 2017;14(6):745–753.
  • Huang Q, Ou YS, Tao Y, Yin H, Tu PH. Apoptosis and autophagy induced by pyropheophorbide-alpha methyl ester-mediated photodynamic therapy in human osteosarcoma MG-63 cells. Apoptosis. 2016;21(6):749–760.
  • Tu PH, Huang WJ, Wu ZL, Peng QZ, Xie ZB, Bao J, Zhong MH. Induction of cell death by pyropheophorbide-alpha methyl ester-mediated photodynamic therapy in lung cancer A549 cells. Cancer medicine. 2017;6(3):631–639.
  • Brozovic A, Ambriovic-Ristov A, Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Critical reviews in toxicology. 2010;40(4):347–359.
  • Li P, Yang X, Cheng Y, Zhang X, Yang C, Deng X, Li P, Tao J, Yang H, Wei J, et al. MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. Cell Physiol Biochem. 2017;41(3):921–932.
  • Yu T, Yang Y, Zhang J, He H, Ren X. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound. Eur J Pharm Biopharm. 2015;91:103–110. doi: 10.1016/j.ejpb.2015.02.003.
  • He H, Yu T, Zhang Y. The interaction between a drug and ultrasound in sonochemotherapy against ovarian cancers. Ultraschall in Med. 2012;33:275–282.
  • Yu T, Luo L, Wang L. Ultrasound as a cancer chemotherapy sensitizer: the gap between laboratory and bedside. Expert Opinion on Drug Delivery. 2015;13(1):37–47.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.